Leerink Partnrs Analysts Lower Earnings Estimates for Nkarta

Nkarta, Inc. (NASDAQ:NKTX - Free Report) - Stock analysts at Leerink Partnrs dropped their Q2 2025 earnings per share (EPS) estimates for Nkarta in a research report issued to clients and investors on Thursday, May 15th. Leerink Partnrs analyst D. Graybosch now forecasts that the company will earn ($0.40) per share for the quarter, down from their prior forecast of ($0.39). The consensus estimate for Nkarta's current full-year earnings is ($1.70) per share. Leerink Partnrs also issued estimates for Nkarta's Q3 2025 earnings at ($0.38) EPS, Q4 2025 earnings at ($0.37) EPS, FY2025 earnings at ($1.59) EPS, FY2026 earnings at ($1.72) EPS, FY2027 earnings at ($2.03) EPS, FY2028 earnings at ($1.78) EPS and FY2029 earnings at ($1.58) EPS.

Nkarta (NASDAQ:NKTX - Get Free Report) last posted its quarterly earnings data on Wednesday, May 14th. The company reported ($0.43) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.44) by $0.01.

A number of other equities analysts also recently issued reports on NKTX. William Blair reiterated a "market perform" rating on shares of Nkarta in a report on Thursday. Stifel Nicolaus decreased their price objective on Nkarta from $15.00 to $14.00 and set a "buy" rating for the company in a report on Thursday, March 27th. HC Wainwright reiterated a "buy" rating and issued a $18.00 price objective on shares of Nkarta in a report on Thursday, March 27th. Finally, Needham & Company LLC cut their target price on Nkarta from $11.00 to $10.00 and set a "buy" rating on the stock in a research note on Thursday. One analyst has rated the stock with a hold rating, five have assigned a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Buy" and an average price target of $14.67.

Nkarta Trading Up 1.2%

NKTX opened at $1.74 on Monday. The stock has a fifty day simple moving average of $1.79 and a two-hundred day simple moving average of $2.19. The company has a market cap of $123.47 million, a price-to-earnings ratio of -0.93 and a beta of 0.81. Nkarta has a 12-month low of $1.31 and a 12-month high of $8.23.

Institutional Investors Weigh In On Nkarta

Institutional investors have recently modified their holdings of the stock. Invesco Ltd. purchased a new stake in shares of Nkarta in the fourth quarter worth $30,000. Sequoia Financial Advisors LLC purchased a new stake in shares of Nkarta in the fourth quarter worth $31,000. Wealth Enhancement Advisory Services LLC purchased a new stake in shares of Nkarta during the first quarter valued at $32,000. China Universal Asset Management Co. Ltd. purchased a new stake in shares of Nkarta during the fourth quarter valued at $37,000. Finally, ProShare Advisors LLC purchased a new stake in shares of Nkarta during the fourth quarter valued at $45,000. 80.54% of the stock is owned by hedge funds and other institutional investors.

About Nkarta

Nkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.